Separately, two additional stem-cell readouts highlighted at ISSCR 2026 pointed to durability and longer-term follow-up for neural cell therapies. In retinitis pigmentosa, data presented on CNS10-NPC described one-year survival of transplanted human neural progenitor cells in the subretinal space with no significant safety concerns. In chronic ischemic stroke, researchers disclosed longer-term clinical and imaging data on hNPC01, a Phase I iPSC-derived forebrain neural progenitor cell therapy. The updates were framed around sustained engraftment-related signals and imaging outcomes across the extended follow-up period. Together, the updates extend the clinical evidence base for iPSC-derived neural progenitors across distinct neurological diseases, reinforcing the field’s focus on both persistence and safety.